BiotechTube
Bioptimus

Bioptimus

Paris, France· Est.
bioptimus.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $70M

Overview

Bioptimus is an emerging leader in AI for biology, leveraging massive datasets and advanced computing to develop foundational AI models that connect biological information from molecules to whole organisms. The company has rapidly gained traction, with its H-Optimus model achieving top rankings in digital pathology and significant adoption in the research community. Backed by $76M in funding and partnerships with leading institutions, Bioptimus is positioned to transform biological research and drug discovery by breaking down data silos and enabling new predictive insights.

OncologyInflammatory Diseases

Technology Platform

AI foundation models for multi-scale, multi-modal biological data, including H-Optimus-1 for histology and M-Optimus as a universal world model of biology.

Funding History

2
Total raised:$70M
Seed$35M
Seed$35M

Opportunities

The massive, growing volume of siloed biological data creates a pressing need for unifying AI models to accelerate drug discovery and diagnostics.
Bioptimus's early leadership in AI for histology provides a beachhead into the large digital pathology market.
Its horizontal platform approach allows for applications across multiple therapeutic areas and partnership types with pharma, diagnostics, and research institutions.

Risk Factors

The core scientific ambition of building a universal biology model is highly complex and may not achieve the desired predictive power.
The company faces intense competition from well-capitalized tech giants and other AI biotechs.
Commercial success depends on securing ongoing access to large, high-quality clinical datasets and navigating potential regulatory pathways for clinical applications.

Competitive Landscape

Bioptimus competes in the crowded AI-for-biology space, facing competition from tech companies (e.g., Google/Isomorphic Labs, NVIDIA), large biopharma internal efforts, and well-funded AI-native biotechs like Recursion, Exscientia, and Owkin. Its differentiation lies in its specific focus on a unified, multi-scale foundation model and its early demonstrated excellence in the digital pathology sub-field.

More companies in AI / Machine Learning →More companies in France →